Skip to content

A prospective, multicenter, randomized controlled, non-inferiority clinical trial to evaluate the safety and efficacy of varicose closure glue in the treatment of varicose veins of the lower extremities.

A prospective, multicenter, randomized controlled, non-inferiority clinical trial to evaluate the safety and efficacy of varicose closure glue in the treatment of varicose veins of the lower extremities.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200059804
Enrollment
Unknown
Registered
2022-05-11
Start date
2022-03-29
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Varicose veins of the lower extremities

Interventions

Experimental group:Varicose closure glue
Controlled group:Radiofrequency ablation catheter

Sponsors

Zhejiang Provincial People‘s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age 18 to 80 years, regardless of gender; 2. Doppler ultrasound confirmed that the valve regurgitation time of saphenofemoral vein was > 0.5 seconds; 3. Doppler ultrasound confirmed that the diameter of great saphenous vein was more than 3mm and less than 15mm; 4. The clinical diagnosis was varicose veins of lower extremities, the clinical symptom grade of CEAP was C2-C5, and the great saphenous vein segment needed to be treated; 5. Patients or their guardians can understand the purpose of the trial, voluntarily participate in and sign the written informed consent form, and can accept follow-up.

Exclusion criteria

Exclusion criteria: 1. The life expectancy is less than 1 year; 2. Great saphenous vein thrombosis; 3. Deep vein thrombosis, or previous history of deep vein thrombosis,pulmonary embolism; 4. Patients with varicose veins of lower extremities with previous surgical intervention; 5. Pregnant or lactating women, or those who plan to become pregnant within one year; 6. Those who are known to be allergic to the drugs, instruments and materials involved in the study; 7. Participate in clinical trials of other experimental biological agents or drugs or devices, and fail to reach the primary endpoint at the time of enrollment; 8. Other conditions in which the patient is not considered suitable for inclusion by the investigator.

Design outcomes

Primary

MeasureTime frame
The rate of complete occlusion of treated segment vein;

Secondary

MeasureTime frame
Success rate of device;Success rate of operation;CEAP clinical symptom classification;Incidence rate of Device defect;Incidence rate of adverse event and Serious adverse event;

Countries

China

Contacts

Public ContactJinsong Jiang

Zhejiang Provincial People‘s Hospital

654614713@qq.com+86 0571-85893385

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026